Various intermittent pneumatic calf compression (IPC) devices are widely used, and have shown improvement in leg swelling and associated pain in patients with CVD or patients undergoing orthopedic or spinal surgery. This has prompted the current study in the observed use, effects and tolerance of mobile sequential pneumatic calf compression. This has been used as the basis for preventative measures in patients with CVD using calf compression stockings, which can be very difficult to wear, and has had recent doubt cast over their efficacy in certain subpopulations. Sustained calf compression is an important part of chronic venous leg ulcer therapy to promote ulcer healing and prevent recurrence. The direct and indirect costs of CVD have been estimated at three billion US dollars per annum. Consequently, it adds to the individual’s suffering, increases morbidity and places a significant burden on the health care system. The calf can become permanently enlarged and hard, and venous ulcers occur more frequently and can be often difficult to heal. Severe and persistent edema leads to secondary lymphedema and marked lower leg swelling. Clinical consequences of CVD include chronic edema, lower limb pain and discomfort, reduced mobility, hyperpigmentation, stasis dermatitis and venous ulcers. Keywords: Vekroosan Calf compression Chronic venous disease IntroductionĬhronic venous disease (CVD) of the lower limbs is caused by abnormalities of the venous wall and valves that lead to obstruction or reflux of blood flow in the veins. Eighty-seven percent of patients tolerated the device well.Ĭonclusions: Our study shows that use of mobile IPC devices, such as Vekroosan, is safe and effective in the treatment of CVD, can be used while mobilizing and can achieve results comparable to non-mobile devices. 21.9 cm, P < 0.01), also with mobilization. A significant decrease was seen in calf swelling after calf compression (31.3 vs. On average, the PFV pressure increased by 10.7 cm/s when compared to baseline. 32.4 cm/s, P < 0.001), even when patients mobilize. There was a significant increase in femoral PFV pressure in post-compression measurement when compared to the pre-compression measurement (43.1 vs. Results: Vekroosan was able to show significant clinical benefit in 45 patients (80%). Methods: In 56 patients, Doppler ultrasonography was used to measure venous blood peak flow velocity (PFV) at external iliac, common femoral, distal superficial femoral and popliteal vein levels both before and after application of Vekroosan calf compressor for comparison. This observational study aimed to note the use, effects and tolerance of a mobile intermittent pneumatic calf compression (IPC) device, Vekroosan ® (DVT Solution P/L). Background: Compression therapy is an essential part of chronic venous disorder (CVD) treatment in reducing associated complications.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |